News & Events about Agios Pharmaceuticals Inc.
Consistent and compelling clinical data across rare hematological diseases support five ongoing pivotal trials in thalassemia, sickle cell disease and pediatric pyruvate kinase (PK) deficiency Driving toward two additional PYRUKYND indications, with potential FDA approvals in thalassemia in 2025 and...
CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 41st AnnualJ.P. Morgan Healthcare ConferenceonWednesday...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Bank of America 2022 Virtual Biotech SMID Cap ...
DekaBank Deutsche Girozentrale bought a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO Get Rating) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 20,000 shares of the biopharmaceutical companys stock, ...
Globe Newswire
3 months ago
Long-term Data for PYRUKYND (mitapivat) in Adults with Pyruvate Kinase (PK) Deficiency and Adults with Thalassemia Demonstrate Sustained Improvement in Hemoglobin, Markers of Hemolysis and Other Disease Impacts New Data from Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts of ...